High mutational burden in ER+ HER2− breast cancer, and ERV3-2 expression in ER− HER2− and HER2+ breast, colon, and endometrial cancers are also associated with over-expression of all three IDO pathway genes, so these features may predict benefit from IDO-1 inhibitors. This evidence concerns the gene ERV3-1 and breast cancer.